Biomarkers correlated with immunogenicity such as tumor‐infiltrating lymphocytes (TIL) levels, PD‐L1 expression and tumor mutational burden (TMB) are reportedly more frequent in the HER2+ relative to the luminal subtypes of BC.120, 121, 122. This evidence concerns the gene ERBB2 and breast cancer.